id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2002-N-0279-0027,FDA,FDA-2002-N-0279,Tab 20 - [Reference (Drug Expenditure Tables)] - Background Material,Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T22:02:41Z,,0,0,090000648049e6cc
FDA-2002-N-0279-0016,FDA,FDA-2002-N-0279,"Tab 4 - [Reference (FDA to Lord, Bissell & Brook on Behalf of Apotex, Inc. Citizen Petition)] - Background Material",Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T21:14:06Z,,0,0,090000648049e6c6
FDA-2002-N-0279-0024,FDA,FDA-2002-N-0279,"Tab 14 - [Reference (Congressional Budget Office ""How Increased Competition from Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry"" (July 1998))] - Background Material",Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T21:14:20Z,,0,0,090000648049e6c9
FDA-2002-N-0279-0013,FDA,FDA-2002-N-0279,"Tab 1 - [Reference ""FTC Citizen Petiton""] - Background Material",Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T21:14:06Z,,0,0,090000648049e6bc
FDA-2002-N-0279-0017,FDA,FDA-2002-N-0279,"Tab 5 - [Reference (Guidance for Industry ""Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients"")] - Background Material",Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T21:14:06Z,,0,0,090000648049e6c7
FDA-2002-N-0279-0019,FDA,FDA-2002-N-0279,"Tab 7 - [Reference Andrx Pharmaceuticals, Inc. v. Biovail Corporation International and Tommy Thompson, Secretary DHHS] - Background Material",Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T21:14:07Z,,0,0,090000648049e6cd
FDA-2002-N-0279-0022,FDA,FDA-2002-N-0279,"Tab 10 - [Reference ""The Patent Term Restoration Act of 1983""] (page 48, 56 and 57  Lewis A. Engman Comment)] - Background Material",Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T21:14:20Z,,0,0,090000648049e6c3
FDA-2002-N-0279-0020,FDA,FDA-2002-N-0279,"Tab 8 - [Reference ""Congressional House"" (Page H 6916 thru H 6921 (9/13/1982))] - Background Material",Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T21:14:19Z,,0,0,090000648049e6bf
FDA-2002-N-0279-0012,FDA,FDA-2002-N-0279,Reference Listing - [Tab 1 thru 19 Reference Title List] - Background Material,Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T21:13:53Z,,0,0,090000648049e6bd
FDA-2002-N-0279-0026,FDA,FDA-2002-N-0279,"Tab 19 - [Reference ""National Health Care Expenditures Projections: 2001-2011"" (Centers for Medicare & Medicaid Services - Office of the Actuary)] - Background Material",Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T22:01:17Z,,0,0,090000648049e6cb
FDA-2002-N-0279-0021,FDA,FDA-2002-N-0279,"Tab 9 - [Reference ""Congressional House"" (Page H 6922 thru H 6924 (9/13/1982))] - Background Material",Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T21:14:20Z,,0,0,090000648049e6c1
FDA-2002-N-0279-0014,FDA,FDA-2002-N-0279,"Tab 2 - [Reference ""Generic Drug Entry Prior to Patent Expiration"" (An FTC Study (July 2002))] - Background Material",Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T21:57:55Z,,0,0,090000648049e6c0
FDA-2002-N-0279-0015,FDA,FDA-2002-N-0279,Tab 3 - [Reference (FDA to Biovail Laboratories Inc.)]  - Background Material,Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T21:14:06Z,,0,0,090000648049e6c4
FDA-2002-N-0279-0018,FDA,FDA-2002-N-0279,"Tab 6 - [Reference (FDA to Beers, Korn, Arnold & Porter, McNichol, Scheineson, Frisch, Smith (Petiton Denial))] - Background Material",Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T21:14:07Z,,0,0,090000648049e6c8
FDA-2002-N-0279-0025,FDA,FDA-2002-N-0279,"Tab 16 - [Reference  ""The Pediatric Exclusivity Provision - January 2001 Status Report to Congress"" [DHHS/FDA]] - Background Material",Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T21:49:03Z,,0,0,090000648049e6ca
FDA-2002-N-0279-0023,FDA,FDA-2002-N-0279,Tab 11 - [Reference (Mr. Kastenmeier Report from Judiciary Committee)] - Background Material,Supporting & Related Material,Reference (external attachments),2011-11-17T05:00:00Z,2011,11,,,2011-11-17T21:14:20Z,,0,0,090000648049e6c5